Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?

Nature Clinical Practice Rheumatology

Volumn 2, Issue 7, 2006, Pages 346-347

  Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE DURATION; DRUG COST; FUNCTIONAL STATUS; HEALTH ECONOMICS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ECONOMICS, PHARMACEUTICAL; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745747252     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0218     Document Type: Review

References (10)

1. Kavanaugh A et al. (2004) The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol 31: 1881-1884
2. Wong J (2005) Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 22 (Suppl 35): S65-S70
3. Kavanaugh A:IHealth economics: implications for novel antirheumatic therapies. Ann Rheum Dis, in press
4. Yelin E and Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline. Arthritis Rheum 42: 1209-1218
5. Kobelt G et al. (2002) Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 46: 2310-2319
6. Lajas C et al. (2003) Costs and predictors of costs in rheumatoid arthritis: A prevalence based study. Arthritis Rheum (Arthritis Care Res) 49: 64-70
7. Wolfe F et al. (2004) Do rheumatology cost-effectiveness analyses make sense? Rheumatology (Oxford) 43: 4-6
8. Hallert E et al. (2004) Rheumatoid arthritis is already expensive during the first year of disease (the Swedish TIRA project). Rheumatology (Oxford) 43: 1374-1382
9. Quinn M et al. (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis Rheum 52: 27-35
10. Machold KP et al. (2002) Very recent onset arthritis - clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29: 2278-2287